Ashley E Pérez1, Madina Agénor2, Kristi E Gamarel3, Don Operario3. 1. Brown University School of Public Health, Providence, Rhode Island. Electronic address: ashley_perez@alumni.brown.edu. 2. Harvard T.H. Chan School of Public Health, Boston, Massachusetts. 3. Brown University School of Public Health, Providence, Rhode Island.
Abstract
INTRODUCTION: Several studies have identified disparities in human papillomavirus (HPV)-related outcomes by nativity status (i.e., U.S.- versus foreign-born). However, few studies have explored whether vaccination differences exist by nativity status. Vaccination disparities have the potential to exacerbate HPV-related cancer disparities in the long term if left unaddressed. Therefore, the authors investigated whether there were significant differences in HPV vaccination initiation (one or more doses) and completion (three or more doses) between U.S.-born and foreign-born men and women. METHODS: Using the 2011 to 2015 waves of the National Health Interview Survey, data from 15,967 U.S. men aged 18-32 years and 23,794 U.S. women aged 18-35 years were analyzed in February 2017. Multivariable logistic regression models were fit to determine whether nativity status predicted (1) HPV vaccination initiation and (2) HPV vaccination completion separately among men and women after adjusting for demographic, socioeconomic, and healthcare factors. RESULTS: Compared with those born in the U.S., foreign-born men and women had lower prevalence of HPV vaccine initiation and completion. Furthermore, after controlling for covariates, foreign-born men (OR=0.63, 95% CI=0.47, 0.85) and women (OR=0.57, 95% CI=0.49, 0.66) had significantly lower adjusted odds of HPV vaccination initiation compared with their U.S.-born counterparts. Additionally, foreign-born women had significantly lower adjusted odds of HPV vaccination completion (OR=0.56, 95% CI=0.46, 0.69). CONCLUSIONS: The demographic, socioeconomic, and healthcare factors included in this study did not appear to account fully for observed disparities. Future research is needed to understand other factors that may contribute to nativity status disparities in HPV vaccination.
INTRODUCTION: Several studies have identified disparities in human papillomavirus (HPV)-related outcomes by nativity status (i.e., U.S.- versus foreign-born). However, few studies have explored whether vaccination differences exist by nativity status. Vaccination disparities have the potential to exacerbate HPV-related cancer disparities in the long term if left unaddressed. Therefore, the authors investigated whether there were significant differences in HPV vaccination initiation (one or more doses) and completion (three or more doses) between U.S.-born and foreign-born men and women. METHODS: Using the 2011 to 2015 waves of the National Health Interview Survey, data from 15,967 U.S. men aged 18-32 years and 23,794 U.S. women aged 18-35 years were analyzed in February 2017. Multivariable logistic regression models were fit to determine whether nativity status predicted (1) HPV vaccination initiation and (2) HPV vaccination completion separately among men and women after adjusting for demographic, socioeconomic, and healthcare factors. RESULTS: Compared with those born in the U.S., foreign-born men and women had lower prevalence of HPV vaccine initiation and completion. Furthermore, after controlling for covariates, foreign-born men (OR=0.63, 95% CI=0.47, 0.85) and women (OR=0.57, 95% CI=0.49, 0.66) had significantly lower adjusted odds of HPV vaccination initiation compared with their U.S.-born counterparts. Additionally, foreign-born women had significantly lower adjusted odds of HPV vaccination completion (OR=0.56, 95% CI=0.46, 0.69). CONCLUSIONS: The demographic, socioeconomic, and healthcare factors included in this study did not appear to account fully for observed disparities. Future research is needed to understand other factors that may contribute to nativity status disparities in HPV vaccination.
Authors: Djin Lai; Julia Bodson; France A Davis; Doriena Lee; Fahina Tavake-Pasi; Edwin Napia; Jeannette Villalta; Valentine Mukundente; Ryan Mooney; Heather Coulter; Louisa A Stark; Ana C Sanchez-Birkhead; Deanna Kepka Journal: J Community Health Date: 2017-04
Authors: S J Rolnick; E D Parker; J D Nordin; B D Hedblom; F Wei; T Kerby; J M Jackson; A L Crain; G Euler Journal: Vaccine Date: 2013-06-24 Impact factor: 3.641
Authors: Lauri E Markowitz; Eileen F Dunne; Mona Saraiya; Harrell W Chesson; C Robinette Curtis; Julianne Gee; Joseph A Bocchini; Elizabeth R Unger Journal: MMWR Recomm Rep Date: 2014-08-29
Authors: Emily A Groene; Keith J Horvath; Nicholas Yared; Inari Mohammed; Miriam Muscoplat; Sydney Kuramoto; Tyler Richter; Shalini Kulasingam Journal: Public Health Rep Date: 2021-07-12 Impact factor: 3.117
Authors: Eric Adjei Boakye; Wenhui Zeng; Samuel Governor; Shreya Nagendra; Betelihem B Tobo; Matthew C Simpson; Nosayaba Osazuwa-Peters Journal: Prev Med Rep Date: 2019-10-25